The measurement of neutralizing antibodies (NAbs) to biological therapeutic agents is important clinically as well as for the preclinical evaluation of product immunogenicity. To determine whether the theoretical concepts and experimental data from studies of the nature of antibody neutralization of interferons (IFNs) can apply to unrelated protein effector molecules, neutralization experiments were undertaken with interleukin-6 (IL-6), a proinflammatory, highly pleiotropic cytokine. By following IL-6 induction of hybridoma cell growth, we demonstrated that anti-IL-6 monoclonal and polyclonal NAbs can be measured with a bioassay design structured to reduce 10 Laboratory Units (LU)/mL to 1 LU/mL. Results are reported in Ten-fold Reduction Units (TRU)/mL, as recommended for the standardization of IFN NAb unitage. The bioassay was shown to be sensitive, reproducible, and robust in measuring IL-6 potency and NAb titer, as well as for evaluating dose–response curve slope differences. This bioassay design should be applicable to any cytokine, growth factor, protein hormone, or similar effector molecules for which an adequately sensitive cellular response can be quantified.
Get full access to this article
View all access options for this article.
References
1.
AndzhaparidzeOG, AyresJJ, De MaeyerE, FinterN, FriedmanR, GrossbergSE, KramerSM, LaughlinCA, LeibowitzPJ. 1988. WHO expert committee on biological standardization. thirty-eighth report. annex l. standardization of interferons: Report of a WHO informal consultation. World Health Organ Tech Rep, 771:37–87.
2.
BergK, BilliauA, De MaeyerE, FinterN, GalassoGJ, GrossbergSE, HilfenhausJ, KawadeY, deJ, LimontaM, MeagerA, OdenEM, PerkinsFT, van RamshortsJD, VilcekJ, TestaD, TrownPW. 1983. WHO expert committee on biological standardization. thirty-third report. annex 1. standardization of interferons. World Health Organ Tech Rep, 687:35–60.
3.
BilliauA, DennisP, De MaeyerE, FinterN, GalassoGJ, GrossbergSE, HilfenhausJ, deJ, LimontaM, MeagerA, OdenEM, PetranyiG, SurprenantH, TestaD, TrownPW, VilcekJ, YamazakeS. 1985. WHO expert committee on biological standardization. thirty-fifth report. annex 1. standardization of interferons. World Health Organ Tech Rep, 725:28–64.
4.
CalamDH, DrozdovSG, GustID, HardegreeMC, LemoinePE, LyngJ, OfosuFA, TanI, Hai-junZ. 1995. World health organization expert committee on biological standardization. forty-fifth report. annex 4 biological substances: International standards and reference reagents. World Health Organ Tech Rep, 858:93.
5.
FilesJG, HargroveD, DeluteL, CantillonM. 2007. Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay. J Interferon Cytokine Res, 27,8:637–642.
6.
Gaines DasRE, PooleS. 1993. The international standard for interleukin-6. evaluation in an international collaborative study. J Immunol Methods, 160,2:147–153.
7.
GrossbergSE, TaylorJL, SiebenlistRE, JamesonP. 1986. Biological and immunological assays of human interferons. RoseNR, FriedmanR, FaheyJL. Manual of clinical immunology, 3rd. Washington, DC: ASM Publishing, 295–299.
8.
GrossbergSE, KawadeY. 1997. The expression of potency of neutralizing antibodies for interferons and other cytokines. Biotherapy, 10,1:93–98.
9.
GrossbergSE, KawadeY, KohaseM, YokoyamaH, FinterN. 2001a. The neutralization of interferons by antibody. I. quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res, 21,9:729–742.
10.
GrossbergSE, KawadeY, KohaseM, KleinJP. 2001b. The neutralization of interferons by antibody. II. neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res, 21,9:743–755.
11.
GrossbergSE, KawadeY. 2006. The development and measurement of antibodies to interferon. MeagerA. The interferons: Characterization and application. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co, 375–399.
12.
GrossbergSE, KawadeY, GrossbergLD. 2009. The neutralization of Interferons by Antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels. J Interferon Cytokine Res, 29,2:93–104.
13.
GuptaS, IndelicatoSR, JethwaV, KawabataT, KelleyM, Mire-SluisAR, RichardsSM, RupB, ShoresE, SwansonSJ, WakshullE. 2007. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods, 321,1–2:1–18.
14.
HelleM, BoeijeL, AardenLA. 1988. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol, 18,10:1535–1540.
15.
JanewayCA, TraversP, WalportJ, ShlomchikMJ. 2005. Immunobiology, 6th. New York, NY: Garland Publishing, 823.
16.
KawadeY. 1980. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titer. J Interferon Res, 1,1:61–70.
17.
KawadeY, WatanabeY. 1984. Neutralization of interferon by antibody: Appraisals of methods of determining and expressing the neutralization titer. J Interferon Res, 4,4:571–584.
18.
KawadeY, WatanabeY. 1985. The nature of neutralization reaction between effector protein and monoclonal antibody: a quantitative study of neutralization characteristics of anti-interferon antibodies. Immunology, 56,3:489–495.
19.
KawadeY. 1986. Quantitation of neutralization of interferon by antibody. Meth Enzymol, 119:558–573.
20.
KawadeY, FinterN, GrossbergSE. 2003. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J Immunol Methods, 278,1–2:127–144.
21.
LallemandC, MarieteJ, EricksonR, GrossbergSE, RoulletE, Lyon-CaenO, LebonP, ToveyMG. 2008. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res, 28:393–404.
22.
LamR, FarrellR, AzizT, GibbsE, GiovannoniG, GrossbergS, OgerJ. 2008. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods, 336,2:113–118.
23.
Morales-MontorJ. 2005. The role of the pleiotropic cytokine interleukin-6 (IL-6) during disease. MAI, 16:21–26.
24.
NakaharaH, NishimotoN. 2006. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. Endocr Metab Immune Disord Drug Targets, 6,4:373–381.
25.
NovickD, EshharZ, RevelM, MoryY. 1989. Monoclonal antibodies for affinity purification of IL-6/IFN-β2 and for neutralization of HGF activity. Hybridoma, 8,5:561–567.
26.
OhsugiY. 2007. Recent advances in IL-6 related to autoimmunity. The Scientist, 21,5:s36.
27.
PapanicolaouDA, WilderRL, ManolagasSC, ChrousosGP. 1998. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med, 128,2:127–137.
28.
PorterS. 2001. Human immune response to recombinant human proteins. J Pharm Sci, 90,1:1–11.
29.
PungorEJr, FilesJG, GabeJD, DoLT, FoleyWP, GrayJL, NelsonJW, NestaasE, TaylorJL, GrossbergSE. 1998. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res, 18,12:1025–1030.
30.
RedlichPN, GrossbergSE. 1989. Analysis of antigenic domains on natural and recombinant human IFN-beta by the inhibition of biologic activities with monoclonal antibodies. J Immunol, 143,6:1887–1893.
31.
SchellekensH. 2003. The immunogenicity of biopharmaceuticals. Neurology, 61,9 Suppl 5:S11–S12.
32.
Van SnickJ. 1990. Interleukin-6: An overview. Annu Rev Immunol, 8:253–278.
33.
VeldhoenM, HockingRJ, AtkinsCJ, LocksleyRM, StockingerB. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity, 24,2:179–189.
34.
WendlingD, RacadotE, WijdenesJ. 1993. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol, 20,2:259–262.
